Top

Published in:

01-09-2018 | Original Article

Pregnancy management and outcome in patients with four different tetrahydrobiopterin disorders

Authors: O. Kuseyri, A. Weissbach, N. Bruggemann, C. Klein, M. Giżewska, D. Karall, S. Scholl-Bürgi, H. Romanowska, E. Krzywińska-Zdeb, A. A. Monavari, I. Knerr, Z. Yapıcı, V. Leuzzi, T. Opladen

Published in: Journal of Inherited Metabolic Disease | Issue 5/2018

Abstract

Introduction

Inborn errors of tetrahydrobiopterin (BH₄) biosynthesis or recycling are a group of very rare neurometabolic diseases. Following growing awareness and improved availability of drug treatment the number of patients with BH₄ disorders reaching adulthood is constantly increasing. Pregnancy care of patients with these disorders is therefore a new challenge for clinicians.

Methods

This retrospective study summarises for the first time clinical and biochemical monitoring data of 16 pregnancies in seven women with different disorders of BH₄ metabolism and evaluates treatment regimens before and during pregnancy in relation to the obstetrical outcome and paediatric follow-up.

Results

Worsening of pre-existing neurological symptoms or occurrence of new symptoms during pregnancy was not observed in most of the cases. Treatment regimens remained mostly unchanged. Pregnancies were not complicated by disease-specific features. Organ abnormalities, miscarriage, prematurity, IUGR and chromosomal changes were occasionally reported, without showing any association with the standard drug treatment for BH₄ deficiencies.

Conclusion

Although our data on 16 pregnancies in seven patients did not present any association of standard drug treatment with an increased rate of pregnancy complications, abnormal obstetrical or paediatric outcome, an intensive clinical and biochemical supervision by a multidisciplinary team before, during and after the pregnancy in any BH₄ deficiency is essential since available data on pregnancies in patients with BH₄ deficiencies is limited.

Available only for authorised users

Allain H, Bentue-Ferrer D, Milon D, Moran P, Jacquemard F, Defawe G (1989) Pregnancy and parkinsonism. A case report without problem. Clin Neuropharmacol 12(3):217–219PubMedCrossRef

American Academy of Pediatrics Committee on Genetics (2008) Policy statement: maternal phenylketonuria. Pediatrics 122:445–449CrossRef

Arai H, Shinotoh H, Hattori T (1997) L-dopa/benserazide during pregnancy in a patient with juvenile parkinsonism. Rinsho Shinkeigaku 37(3):264–265PubMed

Ball MC, Sagar HJ (1995) Levodopa in pregnancy. Mov Disord 10(1):115PubMedCrossRef

Bartholome K (1974) Letter: a new molecular defect in phenylketonuria. Lancet 2(7896):1580PubMedCrossRef

Basson CT, Cowley GS, Solomon SD et al (1994) The clinical and genetic spectrum of the Holt-Oram syndrome (heart-hand syndrome). N Engl J Med 330(13):885–891PubMedCrossRef

Beck S, Wojdyla D, Say L et al (2010) The worldwide incidence of preterm birth: a systematic review of maternal mortality and morbidity. Bull World Health Organ 88(1):31–38PubMedCrossRef

Benbir G, Ertan S, Ozekmekci S (2014) Successful pregnancy and delivery in a patient with Parkinson's disease under pramipexole treatment. Presse Med 43(1):83–85PubMedCrossRef

Benetello P, Furlanut M, Zara G, Baraldo M, Hassan E (1993) Plasma levels of levodopa and its main metabolites in parkinsonian patients after conventional and controlled-release levodopa-carbidopa associations. Eur Neurol 33(1):69–73PubMedCrossRef

Benito-Leon J, Bermejo F, Porta-Etessam J (1999) Pregnancy in Parkinson's disease: a review of the literature and a case report. Mov Disord 14(1):194PubMedCrossRef

Blau N, Thöny B, Cotton R, Hyland K (2001) Disorders of tetrahydrobiopterin and related biogenic amines. McGraw-Hill, New York

Blau N, van Spronsen FJ (2014) Disorders of phenylalanine and tetrahydrobiopterin metabolism. In: Blau N, Duran M, Dionisi-vici C (eds) Physician's guide to the diagnosis, treatment, and follow-up of inherited metabolic diseases. Springer, Heidelberg, pp 3–21

Bruggemann N, Spiegler J, Hellenbroich Y et al (2012) Beneficial prenatal levodopa therapy in autosomal recessive guanosine triphosphate cyclohydrolase 1 deficiency. Arch Neurol 69(8):1071–1075PubMedCrossRef

Brunelli S, Faiella A, Capra V et al (1996) Germline mutations in the homeobox gene EMX2 in patients with severe schizencephaly. Nat Genet 12(1):94–96PubMedCrossRef

Capra V, De Marco P, Moroni A et al (1996) Schizencephaly: surgical features and new molecular genetic results. Eur J Pediatr Surg 6(Suppl 1):27–29PubMedCrossRef

Choi TY, Lee HM, Park WK, Jeong SY, Moon HS (2014) Spontaneous abortion and recurrent miscarriage: a comparison of cytogenetic diagnosis in 250 cases. Obstet Gynecol Sci 57(6):518–525PubMedPubMedCentralCrossRef

Cook DG, Klawans HL (1985) Levodopa during pregnancy. Clin Neuropharmacol 8(1):93–95PubMedCrossRef

Dhondt J-L (2006) Follow-up and outcome of tetrahydrobiopterin deficiencies. In Blau, N PKU and BH4: advances in phenylketonuria and tetrahydrobiopterin. Heilbronn, SPS Verlagsgesellschaft, pp 652–677

Dostal M, Weber-Schoendorfer C, Sobesky J, Schaefer C (2013) Pregnancy outcome following use of levodopa, pramipexole, ropinirole, and rotigotine for restless legs syndrome during pregnancy: a case series. Eur J Neurol 20(9):1241–1246PubMedCrossRef

Douglas G, Hale AB, Crabtree MJ et al (2015) A requirement for Gch1 and tetrahydrobiopterin in embryonic development. Dev Biol 399(1):129–138PubMedPubMedCentralCrossRef

Feillet F, Muntau AC, Debray FG et al (2014) Use of sapropterin dihydrochloride in maternal phenylketonuria. A European experience of eight cases. J Inherit Metab Dis 37(5):753–762PubMedCrossRef

Felix JF, de Jong EM, Torfs CP, de Klein A, Rottier RJ, Tibboel D (2009) Genetic and environmental factors in the etiology of esophageal atresia and/or tracheoesophageal fistula: an overview of the current concepts. Birth Defects Research Part A: Clin Molec Teratol 85(9):747–754CrossRef

Fenton TR, Kim JH (2013) A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants. BMC Pediatr 13:59PubMedPubMedCentralCrossRef

Friedman J, Roze E, Abdenur JE et al (2012) Sepiapterin reductase deficiency: a treatable mimic of cerebral palsy. Ann Neurol 71(4):520–530PubMedCrossRef

Gershanik OS, Leist A (1987) Juvenile onset Parkinson's disease. Adv Neurol 45:213–216PubMed

Gizewska M, Hnatyszyn G, Sagan L et al (2009) Maternal tetrahydrobiopterin deficiency: the course of two pregnancies and follow-up of two children in a mother with 6-pyruvoyl-tetrahydropterin synthase deficiency. J Inherit Metab Dis 32(Suppl 1):S83–S89PubMedCrossRef

Golbe LI (1987) Parkinson's disease and pregnancy. Neurology 37(7):1245–1249PubMedCrossRef

Grange DK, Hillman RE, Burton BK et al (2014) Sapropterin dihydrochloride use in pregnant women with phenylketonuria: an interim report of the PKU MOMS sub-registry. Mol Genet Metab 112(1):9–16PubMedCrossRef

Hagell P, Odin P, Vinge E (1998) Pregnancy in Parkinson's disease: a review of the literature and a case report. Mov Disord 13(1):34–38PubMedCrossRef

Hanley WB, Clarke JT, Schoonheyt W (1987) Maternal phenylketonuria (PKU)--a review. Clin Biochem 20(3):149–156PubMedCrossRef

Howe DT, Rankin J, Draper ES (2012) Schizencephaly prevalence, prenatal diagnosis and clues to etiology: a register-based study. Ultrasound Obstet Gynecol 39(1):75–82PubMedCrossRef

Irons M, Levy HL, O'Flynn ME et al (1987) Folinic acid therapy in treatment of dihydropteridine reductase deficiency. J Pediatr 110(1):61–67PubMedCrossRef

Jacquemard F, Palaric JC, Allain H, Giraud JR (1990) Parkinson disease and pregnancy. Apropos of a case. J Gynecol Obstet Biol Reprod (Paris) 19(4):461–463

Jaggi L, Zurfluh MR, Schuler A et al (2008) Outcome and long-term follow-up of 36 patients with tetrahydrobiopterin deficiency. Mol Genet Metab 93(3):295–305PubMedCrossRef

Koch R, Moseley K, Guttler F (2005) Tetrahydrobiopterin and maternal PKU. Mol Genet Metab 86(Suppl 1):S139–S141PubMedCrossRef

Kranick SM, Mowry EM, Colcher A, Horn S, Golbe LI (2010) Movement disorders and pregnancy: a review of the literature. Mov Disord 25(6):665–671PubMedCrossRef

Levy HL (2003) Historical background for the maternal PKU syndrome. Pediatrics 112(6 Pt 2):1516–1518PubMed

Mabry CC, Denniston JC, Nelson TL, Son CD (1963) Maternal phenylketonuria. A cause of mental retardation in children without the metabolic defect. N Engl J Med 269:1404–1408PubMedCrossRef

McIntyre S, Badawi N, Blair E, Nelson KB (2015) Does aetiology of neonatal encephalopathy and hypoxic-ischaemic encephalopathy influence the outcome of treatment? Dev Med Child Neurol 57(Suppl 3):2–7PubMedCrossRef

Merchant CA, Cohen G, Mytilineou C et al (1995) Human transplacental transfer of carbidopa/levodopa. J Neural Transm Park Dis Dement Sect 9(2–3):239–242PubMedCrossRef

Mucchiut M, Belgrado E, Cutuli D, Antonini A, Bergonzi P (2004) Pramipexole-treated Parkinson's disease during pregnancy. Mov Disord 19(9):1114–1115PubMedCrossRef

Murphy E (2015) Pregnancy in women with inherited metabolic disease. Obstet Med 8(2):61–67PubMedPubMedCentralCrossRef

Narisawa K, Arai N, Ishizawa S et al (1980) Dihydropteridine reductase deficiency: diagnosis by leukocyte enzyme assay. Clin Chim Acta 105(3):335–342PubMedCrossRef

Nassar N, Leoncini E, Amar E et al (2012) Prevalence of esophageal atresia among 18 international birth defects surveillance programs. Birth Defects Res Part A: Clin Molec Teratol 94(11):893–899CrossRef

Neilson JP, Gyte GM, Hickey M, Vazquez JC, Dou L (2013) Medical treatments for incomplete miscarriage. Cochrane Database Syst Rev 3:CD007223

Nomoto M, Kaseda S, Iwata S, Osame M, Fukuda T (1997) Levodopa in pregnancy. Mov Disord 12(2):261PubMed

Opladen T, Cortès-Saladelafont E, Mastrangelo M et al (2016) The InternationalWorking group on neurotransmitter related disorders (iNTD): a worldwide research project focused on primary and secondary neurotransmitter disorders. Molec Genet Metab Rep 9:61–66CrossRef

Opladen T, Hoffmann G, Horster F et al (2011) Clinical and biochemical characterization of patients with early infantile onset of autosomal recessive GTP cyclohydrolase I deficiency without hyperphenylalaninemia. Mov Disord 26(1):157–161PubMedCrossRef

Opladen T, Hoffmann GF, Blau N (2012) An international survey of patients with tetrahydrobiopterin deficiencies presenting with hyperphenylalaninaemia. J Inherit Metab Dis 35(6):963–973PubMedCrossRef

Pini Prato A, Carlucci M, Bagolan P et al (2015) A cross-sectional nationwide survey on esophageal atresia and tracheoesophageal fistula. J Pediatr Surg 50(9):1441–1456PubMedCrossRef

Ponzone A, Ferraris S, Baglieri S,Spada M (2006) Treatment of tetrahydrobiopterin deficiencies. In Blau, N PKU and BH4: advances in phenylketonuria and tetrahydrobiopterin. Heilbronn, SPS Verlagsgesellschaft, pp 612–637

Rey F, Blandin-Savoja F, Rey J (1976) Atypical phenylketonuria with normal dihydropteridine reductase activity. N Engl J Med 295(20):1138–1139PubMedCrossRef

Routiot T, Lurel S, Denis E, Barbarino-Monnier P (2000) Parkinson's disease and pregnancy: case report and literature review. J Gynecol Obstet Biol Reprod (Paris) 29(5):454–457

Scott M, Chowdhury M (2005) Pregnancy in Parkinson's disease: unique case report and review of the literature. Mov Disord 20(8):1078–1079PubMedCrossRef

Segawa M, Hosaka A, Miyagawa F, Nomura Y, Imai H (1976) Hereditary progressive dystonia with marked diurnal fluctuation. Adv Neurol 14:215–233PubMed

Segawa M, Nomura Y, Nishiyama N (2003) Autosomal dominant guanosine triphosphate cyclohydrolase I deficiency (Segawa disease). Ann Neurol 54(Suppl 6):S32–S45PubMedCrossRef

Serikawa T, Shimohata T, Akashi M et al (2011) Successful twin pregnancy in a patient with parkin-associated autosomal recessive juvenile parkinsonism. BMC Neurol 11:72PubMedPubMedCentralCrossRef

Sharma D, Shastri S, Sharma P (2016) Intrauterine growth restriction: antenatal and postnatal aspects. Clin Med Insights Pediatr 10:67–83PubMedPubMedCentral

Shintaku H, Ohwada M (2013) Long-term follow-up of tetrahydrobiopterin therapy in patients with tetrahydrobiopterin deficiency in Japan. Brain Develop 35(5):406–410

Shulman LM, Minagar A, Weiner WJ (2000) The effect of pregnancy in Parkinson's disease. Mov Disord 15(1):132–135PubMedCrossRef

Steinberger D, Blau N, Goriuonov D et al (2004) Heterozygous mutation in 5′-untranslated region of sepiapterin reductase gene (SPR) in a patient with dopa-responsive dystonia. Neurogenetics 5(3):187–190PubMedCrossRef

Thony B, Blau N (2006) Mutations in the BH4-metabolizing genes GTP cyclohydrolase I, 6-pyruvoyl-tetrahydropterin synthase, sepiapterin reductase, carbinolamine-4a-dehydratase, and dihydropteridine reductase. Hum Mutat 27(9):870–878PubMedCrossRef

Trender-Gerhard I, Sweeney MG, Schwingenschuh P et al (2009) Autosomal-dominant GTPCH1-deficient DRD: clinical characteristics and long-term outcome of 34 patients. J Neurol Neurosurg Psychiatry 80(8):839–845PubMedCrossRef

van der Linde D, Konings EE, Slager MA et al (2011) Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis. J Am Coll Cardiol 58(21):2241–2247PubMedCrossRef

van Spronsen FJ, van Wegberg AM, Ahring K et al (2017) Key European guidelines for the diagnosis and management of patients with phenylketonuria. Lancet Diabetes Endocrinol 5(9):743–756PubMedCrossRef

Ventzke A, Hoffmann J, Crushell E, Monavari A, Mayne PD, Knerr I (2015) 'Malignant Phenylketonuria' (PKU) due to Dihydropteridine reductase (DHPR) deficiency. Ir Med J 108(10):312–314PubMed

Voigt M, Zels K, Guthmann F, Hesse V, Gorlich Y, Straube S (2011) Somatic classification of neonates based on birth weight, length, and head circumference: quantification of the effects of maternal BMI and smoking. J Perinat Med 39(3):291–297PubMedCrossRef

Volpe JJ (2012) Neonatal encephalopathy: an inadequate term for hypoxic-ischemic encephalopathy. Ann Neurol 72(2):156–166PubMedCrossRef

von Graevenitz KS, Shulman LM, Revell SP (1996) Levodopa in pregnancy. Mov Disord 11(1):115–116CrossRef

Watanabe T, Matsubara S (2012) Good obstetric outcome in a patient with Segawa disease. Arq Neuropsiquiatr 70(7):559–560PubMedCrossRef

Watanabe T, Matsubara S, Baba Y, Tanaka H, Suzuki T, Suzuki M (2009) Successful management of pregnancy in a patient with Segawa disease: case report and literature review. J Obstet Gynaecol Res 35(3):562–564PubMedCrossRef

Werner ER, Blau N, Thony B (2011) Tetrahydrobiopterin: biochemistry and pathophysiology. Biochem J 438(3):397–414PubMedCrossRef

Title: Pregnancy management and outcome in patients with four different tetrahydrobiopterin disorders
Authors: O. Kuseyri
A. Weissbach
N. Bruggemann
C. Klein
M. Giżewska
D. Karall
S. Scholl-Bürgi
H. Romanowska
E. Krzywińska-Zdeb
A. A. Monavari
I. Knerr
Z. Yapıcı
V. Leuzzi
T. Opladen
Publication date: 01-09-2018
Publisher: Springer Netherlands
Published in: Journal of Inherited Metabolic Disease / Issue 5/2018
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI: https://doi.org/10.1007/s10545-018-0169-0

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Pregnancy management and outcome in patients with four different tetrahydrobiopterin disorders

Abstract

Introduction

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2018

Editorial

A double-blind, placebo-controlled trial of triheptanoin in adult polyglucosan body disease and open-label, long-term outcome

Medical and financial burden of acute intermittent porphyria

Hepatocellular carcinoma in Gaucher disease: an international case series

Oxygen in mitochondrial disease: can there be too much of a good thing?

Organic acidurias in adults: late complications and management

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page